

November 02, 2018

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip code: 512529

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051
Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Outcome of Board Meeting: Unaudited financial results for the quarter ended September 30, 2018

Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its meeting held today i.e. November 02, 2018 have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2018. In this regard, kindly find attached the following:

1. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2018.
2. Press Release on Financial Results alongwith with investors presentation.
3. Limited Review Report issued by the Statutory Auditors of the Company.

The Board Meeting commenced on 10:15 A.M. and concluded at 11:00 A.M.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited



Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

3. The Statement includes the results of the following entities:

- i) Alivira Animal Health Australia Pty Ltd;
- ii) Alivira Animal Health Limited, Ireland;
- iii) Alivira Animal Health Limited, India;
- iv) Alivira Saude Animal Brasil Participacoes Ltda;
- v) Alivira UA Limited;
- vi) Alivira France;
- vii) Bremer Pharma GMBH;
- viii) Comercial Vila Veterinaria de Lleida S.L;
- ix) Elysian Life Sciences Private Limited;
- x) Fendigo BV;
- xi) Fendigo SA;
- xii) Interchange Veterinária Indústria E Comércio Ltda;
- xiii) Laboratorios Karizoo, S.A;
- xiv) Laboratorios Karizoo, S.A. De C.V. (Mexico);
- xv) N-Vet AB;
- xvi) Phytotherapeutic Solutions S.L;
- xvii) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
- xviii) SeQuent Antibiotics Private Limited;
- xix) SeQuent Pharmaceuticals Private Limited;

Deloitte Haskins & Sells

- xx) SeQuent Research Limited;
- xxi) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
- xxii) Vila Viña Participacions S.L.

4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of twelve subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs 47,465.82 lakhs as at September 30, 2018, total revenues of Rs 16,556.32 lakhs and Rs 32,999.78 lakhs for the quarter and six months ended September 30, 2018, respectively, and total profit after tax of Rs 384.06 lakhs and Rs 918.85 lakhs and total comprehensive income of Rs 384.06 lakhs and Rs 918.85 lakhs for the quarter and six months ended September 30, 2018, respectively, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of this matter.

6. The consolidated unaudited financial results includes the interim financial results of nine subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs 45,385.48 lakhs as at September 30, 2018, total revenue Rs 459.78 lakhs and Rs 894.50 lakhs for the quarter and six months ended September 30, 2018, respectively, and total loss after tax of Rs 263.32 lakhs and Rs 1,069.47 lakhs and total comprehensive loss of Rs 267.32 lakhs and Rs 1,069.47 lakhs for the quarter and six months ended September 30, 2018, respectively, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner

(Membership No. 206920)

Thane, November 02, 2018
SPK/JKS/DSS/2018

Sequent

SEQUENT SCIENTIFIC LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2018

(Rs. in Lakhs)

	Particulars	3 months ended 30-Sep-2018	Preceding 3 months ended 30-Jun-2018	Corresponding 3 months ended in the previous year 30-Sep-2017	Year to date figures for the current period ended 30-Sep-2018	Year to date figures for the previous period ended 30-Sep-2017	Previous year ended 31-Mar-2018
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Revenue from operations (Refer note 6)	25,172.40	23,515.20	19,754.05	48,687.60	39,177.25	84,944.80
II	Other income	244.30	181.40	660.14	425.70	1,022.44	1,658.10
III	Total income (I+II)	25,416.70	23,696.60	20,414.19	49,113.30	40,199.69	86,602.90
IV	Expenses						
	(a). Cost of materials consumed	9,785.00	10,507.60	6,958.98	20,292.60	14,907.10	34,459.40
	(b). Purchase of stock-in-trade	3,457.60	3,354.70	2,845.06	6,812.30	6,330.62	14,184.10
	(c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	(136.30)	(1,211.20)	1,475.00	(1,347.50)	650.00	(2,394.30)
	(d). Excise duty on sale of goods	-	-	-	-	161.02	161.02
	(e). Employee benefits expense	3,446.10	3,513.60	2,806.03	6,959.70	5,487.62	11,382.80
	(f). Finance costs	777.20	778.30	741.64	1,555.50	1,352.01	3,306.90
	(g). Depreciation and amortisation expense	1,020.20	963.80	1,005.22	1,984.00	2,013.53	4,134.30
	(h). Other expenses	5,846.60	5,098.90	3,779.51	10,945.50	8,243.97	18,853.80
	Total expenses	24,196.40	23,005.70	19,611.44	47,202.10	39,145.87	84,088.02
V	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	1,220.30	690.90	802.75	1,911.20	1,053.82	2,514.88
VI	Exceptional items loss/ (Profit) (net) (Refer note 7)	-	-	-	-	-	150.40
VII	Profit/(loss) from continuing operations before tax (V-VI)	1,220.30	690.90	802.75	1,911.20	1,053.82	2,364.48
VIII	Tax expense						
	(a). Current tax (Refer note 8)	32.40	340.70	438.10	373.10	661.40	1,196.80
	(b). MAT credit entitlement	(170.30)	(84.80)	-	(255.10)	-	(3.90)
	(c). MAT credit entitlement written off	-	-	-	-	-	286.70
	(d). Deferred tax	(191.70)	(13.00)	(55.30)	(204.70)	(86.00)	(133.90)
	Total tax expenses (VIII)	(329.60)	242.90	382.80	(86.70)	575.40	1,345.70
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	1,549.90	448.00	419.95	1,997.90	478.42	1,018.78
X	Profit/(loss) from discontinued operations	-	-	883.47	-	1,054.70	1,054.70
	Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations	-	-	1,745.50	-	1,745.50	41,009.50
	Tax expense of discontinued operation						
	(a). Current tax	-	-	-	-	-	362.73
	(b). MAT credit entitlement	-	-	-	-	-	(362.73)
	Profit/(loss) from discontinued operations after tax (Refer note 4a & 4b)	-	-	2,633.97	-	2,800.20	42,064.20
XI	Profit/(loss) for the period (IX+X)	1,549.90	448.00	3,053.92	1,997.90	3,278.62	43,082.98
XII	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a). Re-measurement gain/(loss) on defined benefits plans	27.20	(5.00)	1.20	22.20	(2.40)	82.50
	(b). Fair value gain / (loss) from investment in equity instruments (net)	1,608.50	(7,711.90)	(3,802.80)	(5,103.40)	(7,033.60)	(14,195.41)
	Items that may be reclassified to profit or loss						
	(a). Exchange differences on translation of foreign operations (net)	1,206.62	(136.56)	292.98	1,070.06	226.88	244.66
	(b). Exchange differences on net investment in foreign operations (net)	(989.34)	355.51	48.38	(633.83)	147.16	(2.61)
	Total other comprehensive income for the period	1,852.98	(7,497.95)	(3,460.26)	(5,644.97)	(6,661.96)	(13,871.86)
XIII	Total comprehensive income for the period (XI+XII)	3,402.88	(7,049.95)	(406.34)	(3,647.07)	(3,383.34)	29,211.12
	Profit for the period attributable to:						
	- Owners of the Company	1,523.10	328.00	2,923.92	1,851.10	3,147.62	42,156.58
	- Non-controlling interests	26.80	120.00	130.00	146.80	131.00	926.40
	Other comprehensive income for the period attributable to:						
	- Owners of the Company	1,898.58	(7,433.45)	(3,492.56)	(5,534.87)	(6,761.56)	(13,954.86)
	- Non-controlling interests	(45.60)	(64.50)	32.30	(110.10)	99.60	83.00
	Total comprehensive income for the period attributable to:						
	- Owners of the Company	3,421.68	(7,105.45)	(568.64)	(3,683.77)	(3,613.94)	28,201.72
	- Non-controlling interests	(18.80)	55.50	162.30	36.70	230.60	1,009.40
	Earnings per equity share: (face value of Rs. 2 each) (not annualised)						
	- for continuing operations						
	(1) Basic (in Rs.)	0.63	0.14	0.12	0.76	(0.01)	(0.11)
	(2) Diluted (in Rs.)	0.63	0.13	0.12	0.76	(0.01)	(0.11)
	- for discontinued operations						
	(1) Basic (in Rs.)	-	-	1.09	-	1.31	17.51
	(2) Diluted (in Rs.)	-	-	1.08	-	1.30	17.40
	- for continuing and discontinued operations						
	(1) Basic (in Rs.)	0.63	0.14	1.21	0.76	1.30	17.40
	(2) Diluted (in Rs.)	0.63	0.13	1.20	0.76	1.29	17.29
	See accompanying notes to the financial results						



CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2018

Sl.No.	Particulars	(Rs. in Lakhs)	
		As at 30- Sep- 2018	As at 31- Mar- 2018
		UNAUDITED	AUDITED
(A)	ASSETS		
1	Non-current assets		
(a)	Property, plant and equipment	23,285.10	21,351.40
(b)	Capital work in progress	1,856.50	1,340.60
(c)	Goodwill	22,986.30	20,219.30
(d)	Other intangible assets	5,665.20	6,026.50
(e)	Intangible assets under development	400.40	463.20
(f)	Financial assets		
(i)	Investments	16,076.90	22,173.30
(ii)	Other financial assets	514.70	495.40
(g)	Deferred tax assets (net)	2,356.30	2,119.10
(h)	Income tax assets (net)	230.60	448.10
(i)	Other non-current assets	6,471.00	5,837.80
	Total non current assets	79,843.00	80,474.70
2	Current assets		
(a)	Inventories	19,403.90	15,857.40
(b)	Financial assets		
(i)	Investments	616.40	1,734.50
(ii)	Trade receivables	25,451.80	25,834.90
(iii)	Cash and cash equivalents	5,722.70	3,954.40
(iv)	Bank balances other than (iii) above	137.20	290.40
(v)	Loans	47.90	1,167.70
(vi)	Others financial assets	142.20	191.50
(c)	Other current assets	4,912.90	4,770.70
	Total current assets	56,435.00	53,801.50
	Total Assets	1,36,278.00	1,34,276.20
(B)	EQUITY AND LIABILITIES		
1	Equity		
(a)	Equity share capital	4,874.70	4,874.70
(b)	Other equity	57,663.20	59,882.98
(c)	Non-controlling interest	4,159.40	3,598.50
	Total equity	66,697.30	68,456.18
2	Liabilities		
I	Non-current liabilities		
(a)	Financial Liabilities		
(i)	Borrowings	9,993.50	10,354.50
(ii)	Other financial liabilities	8,023.60	10,293.90
(b)	Long-term provisions	749.20	749.00
(c)	Deferred tax liabilities	1,010.40	1,081.10
(d)	Other non-current liabilities	241.50	248.40
	Total non-current liabilities	20,018.20	22,726.90
II	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	16,674.70	15,240.70
(ii)	Trade payables	18,386.30	16,049.22
(iii)	Other financial liabilities	10,488.30	7,372.80
(b)	Provisions	273.40	254.20
(c)	Current tax liabilities (net)	616.80	897.20
(d)	Other current liabilities	3,118.30	3,279.00
	Total current liabilities	49,562.50	43,093.12
	Total Equity and Liabilities	1,36,278.00	1,34,276.20
	See accompanying notes to the financial results		

Notes:
1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 02 November 2018. The statutory auditors have carried limited review of the above results.
2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

Particulars	(Rs in Lakhs)					
	3 months ended 30-Sep-2018	Preceding 3 months ended 30-Jun-2018	Corresponding 3 months ended in the previous year 30-Sep-2017	Year to date figures for the current period ended 30-Sep-2018	Year to date figures for the previous period ended 30-Sep-2017	Previous year ended 31-Mar-2018
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from continuing operations	3,624.10	2,628.50	2,643.63	6,252.60	5,372.03	10,723.60
Profit/ (Loss) before tax from continuing operations	271.30	261.90	339.77	533.20	66.27	66.30
Profit/ (Loss) after tax from continuing operations	271.30	261.90	339.77	533.20	66.27	(220.37)
Profit/ (Loss) after tax from discontinued operations			850.70		1,707.40	40,861.10
Total comprehensive income	1,892.20	(7,459.00)	(2,580.35)	(5,566.80)	(5,256.25)	26,408.03



Sequent

SEQUENT SCIENTIFIC LIMITED

4a. Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018 ('Order'), with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited ('Solara').

Pursuant to the above, Sequent Penems Private Limited has ceased to be the subsidiary of the Company.

In line with the approved Scheme, the comparative information in these results for the quarter and six months ended 30 September 2017 have been revised from the published financial results for that quarter to exclude the results of Human API business and Sequent Penems Private Limited.

4b. During the previous year ended 31 March 2018, the Company completed the divestment of woman healthcare business (discontinued operations).

The results relating to discontinued business are as follows:

(Rs in Lakhs)						
Particulars	3 months ended 30-Sep-2018	Preceding 3 months ended 30-Jun-2018	Corresponding 3 months ended in the previous year 30-Sep-2017	Year to date figures for the current period ended 30-Sep-2018	Year to date figures for the previous period ended 30-Sep-2017	Previous year ended 31-Mar-2018
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total income	-	-	8,349.80	-	18,575.72	18,575.74
Total expenses	-	-	7,461.33	-	17,521.02	17,521.04
Profit/ (Loss) before exceptional items and tax	-	-	888.47	-	1,054.70	1,054.70
Exceptional items	-	-	-	-	-	-
Profit/ (Loss) before tax	-	-	888.47	-	1,054.70	1,054.70
Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations	-	-	1,745.50	-	1,745.50	41,009.50
Tax Expense of discontinued operations	-	-	-	-	-	-
Profit/ (Loss) for the period	-	-	2,633.97	-	2,800.20	42,064.20

5. With effect from 01 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra for consideration of Rs. 4,540 lakhs. The Company is in process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted for based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations". The revenue from operations for the quarter and six months ended includes Rs. 1,006.20 lakhs relating to Mahad facility and there is no significant impact on profit after tax.

6. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty up to 30 June 2017. Accordingly, revenue from operations for the six months ended 30 September 2018 are not comparable with those of the previous periods presented.

7. Exceptional Items:

(Rs in Lakhs)	
Particulars	Previous year ended 31-Mar-2018
	AUDITED
- Write off of ineligible GST credits	116.10
- Goodwill impairment	750.00
- Contingent consideration reversal	(931.25)
- liability towards pre-acquisition employee claims	175.56
Total	150.40

8. The current tax expenses for the quarter and six months ended 30 September 2018 include reversal of provision for tax of Rs. 317.20 lakhs pertaining to earlier years for one of the subsidiary company on completion of assessment.

9. During the period, the Company has revised the useful life of certain acquired intangible acquired from 5 years to 20 years. Had the useful life been 5 years, the impact on profit is as below:

(Rs in Lakhs)			
Particulars	3 months ended 30-Sep-2018	Preceding 3 months ended 30-Jun-2018	Year to date figures for the current period ended 30-Sep-2018
	UNAUDITED	UNAUDITED	UNAUDITED
Impact on Profit	163.82	167.55	331.37
NCI Share on above	61.85	63.26	125.11

10. 'Ind AS 115 - Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the unaudited financial results of the Company.

11. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish
Manish Gupta
Managing Director



Place : Thane
Date : 02 November 2018

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter and six months ended September 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants
(Firm's Registration No. 008072S)

Sathya P. Koushik

Partner
(Membership No. 206920)

Thane, November 02, 2018
SPK/JKS/DSS/2018

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2018

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in previous period	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
		30-Sep-2018	30-Jun-2018	30-Sep-2017	30-Sep-2018	30-Sep-2017	31-Mar-18
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations (Refer note 3)	3,624.10	2,628.50	2,643.83	6,252.60	5,372.03	10,723.60
II	Other income	456.90	435.60	1,024.93	892.50	1,468.83	2,426.90
III	Total income (I+II)	4,081.00	3,064.10	3,668.76	7,145.10	6,840.86	13,150.50
IV	Expenses						
	(a) Cost of materials consumed	2,239.20	916.10	1,013.85	3,155.30	1,594.85	3,065.70
	(b) Purchases of stock-in-trade	579.00	1,026.60	1,358.10	1,605.60	2,620.10	4,914.30
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(937.30)	(160.80)	137.40	(1,098.10)	137.70	(42.20)
	(d) Excise duty on sale of goods	-	-	-	-	122.90	122.90
	(e) Conversion and processing charges	912.30	398.00	105.32	1,310.30	343.52	1,175.60
	(f) Employee benefits expense	262.00	157.50	399.29	419.50	762.89	1,185.00
	(g) Finance costs	6.20	1.30	7.19	7.50	24.69	39.20
	(h) Depreciation and amortisation expense	178.50	87.70	81.66	266.20	157.16	366.70
	(i) Other expenses	569.80	375.80	226.18	945.60	1,010.78	2,140.90
	Total expenses	3,809.70	2,802.20	3,328.99	6,611.90	6,774.59	12,968.10
V	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	271.30	261.90	339.77	533.20	66.27	182.40
VI	Exceptional items loss / (gain) (net) (Refer note 5)	-	-	-	-	-	115.10
VII	Profit/(loss) from continuing operations before tax (V-VI)	271.30	261.90	339.77	533.20	66.27	66.30
VIII	Tax expense						
	(a) Current tax	58.00	55.60	-	113.60	-	3.87
	(b) MAT credit entitlement	(58.00)	(55.60)	-	(113.60)	-	(3.87)
	(c) MAT credit entitlement written off	-	-	-	-	-	286.67
	Total tax expenses	-	-	-	-	-	286.67
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	271.30	261.90	339.77	533.20	66.27	(220.37)
X	Profit/(loss) from discontinued operations	-	-	880.70	-	1,707.40	1,707.40
	Gain on demerger of Hurnan API business (Refer note 7)	-	-	-	-	-	39,153.70
	Tax expense of discontinued operations						
	(a) Current tax	-	-	-	-	-	362.73
	(b) MAT credit entitlement	-	-	-	-	-	(362.73)
	Profit/(loss) from discontinued operations after tax	-	-	880.70	-	1,707.40	40,861.10
XI	Profit/(loss) for the period (IX+X)	271.30	261.90	1,220.47	533.20	1,773.67	40,640.73
XII	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurements gain / (loss) on defined benefits plans	12.40	(9.00)	1.78	3.40	3.68	(37.30)
	(b) Fair value gain / (loss) from investment in equity instruments (net)	1,608.50	(7,711.90)	(3,802.80)	(6,103.40)	(7,033.60)	(14,195.40)
	Total other comprehensive income for the period	1,620.90	(7,720.90)	(3,801.02)	(6,100.00)	(7,029.92)	(14,232.70)
XIII	Total comprehensive income for the period (XI+XII)	1,892.20	(7,459.00)	(2,580.55)	(5,566.80)	(5,256.25)	26,408.03
	Earnings per equity share: (Face value of Rs. 2 each) (not-annualised)						
	- for continuing operations						
	(1) Basic (in Rs.)	0.11	0.11	0.14	0.22	0.03	(0.09)
	(2) Diluted (in Rs.)	0.11	0.11	0.14	0.22	0.03	(0.09)
	- for discontinued operations						
	(1) Basic (in Rs.)	-	-	0.36	-	0.70	16.66
	(2) Diluted (in Rs.)	-	-	0.36	-	0.70	16.75
	- for continuing and discontinued operations						
	(1) Basic (in Rs.)	0.11	0.11	0.50	0.22	0.73	16.77
	(2) Diluted (in Rs.)	0.11	0.11	0.50	0.22	0.73	16.66
	See accompanying notes to financial results						



Sequent

Proven Ability to Life Sciences
SEQUENT SCIENTIFIC LIMITED

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2018

(Rs. in Lakhs)

Particulars	As at 30-Sep-2018	As at 31-Mar-2018
	Unaudited	Audited
A ASSETS		
1. Non-current assets		
(a) Property plant and equipment	4,544.30	1,890.70
(b) Capital work-in-progress	261.20	153.10
(c) Investment property	-	-
(d) Intangible assets	522.70	477.60
(e) Intangible assets under development	-	159.00
(f) Financial assets		
(i) Investments		
(a) Investments in subsidiaries	45,196.20	45,100.40
(b) Other investments	16,070.10	22,166.90
(ii) Loans	16,245.90	11,417.90
(iii) Other financial assets	81.30	60.60
(g) Deferred tax assets (net)	651.00	537.40
(h) Income tax assets (net)	8.50	134.60
(i) Other non-current assets	2,312.20	1,594.80
Total non-current assets	85,893.40	83,693.00
2. Current assets		
(a) Inventories	3,096.30	1,383.30
(b) Financial assets		
(i) Investments	593.20	1,398.20
(ii) Trade receivables	5,525.40	7,846.60
(iii) Cash and cash equivalents	857.10	99.60
(iv) Bank balances other than (iii) above	84.20	204.90
(v) Loans	5.80	1,122.30
(vi) Other financial assets	72.10	54.80
(c) Other current assets	1,876.90	1,944.70
Total current assets	12,111.00	14,054.40
Total assets	98,004.40	97,747.40
B EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	4,874.70	4,874.70
(b) Other equity	84,523.50	89,987.00
Total equity	89,398.20	94,861.70
II Liabilities		
1. Non-current liabilities		
(a) Provisions	277.40	216.70
Total non-current liabilities	277.40	216.70
2. Current liabilities		
(a) Financial liabilities		
(i) Trade payables	5,357.30	2,456.40
(ii) Other financial liabilities	2,918.70	128.20
(b) Other current liabilities	34.90	63.20
(c) Provisions	17.90	21.20
Total current liabilities	8,328.80	2,669.00
Total liabilities	8,606.20	2,885.70
Total equity and liabilities	98,004.40	97,747.40
See accompanying notes to financial results		



Sequent

Pharmaceuticals Ltd. & Co. Pvt. Ltd.

SEQUENT SCIENTIFIC LIMITED

Notes:

- 1 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 02 November 2018. The statutory auditors have carried limited review of the above results.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty upto 30 June 2017. Accordingly, revenue from operations for the six months ended 30 September 2018 are not comparable with those of the previous periods presented.
- 4 With effect from 01 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra for consideration of Rs. 4,640 lakhs. The Company is in process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations". The revenue from operations for the quarter and six months ended 30 September 2018 includes Rs. 1,449.60 lakhs relating to Mahad facility and there is no significant impact on profit after tax.
- 5 Exceptional items for the year ended 31 March 2018 comprises write-off of ineligible GST credits.
- 6 Tax expenses has been accrued during the current quarter and six months ended based on estimated Minimum Alternate Tax applicable to the entity and for previous periods, tax expenses are split between continuing and discontinued operations based on book profits from the respective operations.
- 7 Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018, with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited. In line with the approved Scheme, the comparative information in these results for the quarter ended 30 September 2017 have been revised from the published financial results for that quarter to exclude the result of the Human API business which had a revenue of Rs. 8,334.00 lakhs and expenses of Rs. 7,453.30 lakhs.

(Rs. in Lakhs)

Particulars	3 months ended 30-Sep-2018	Preceding 3 months ended 30-Jun-2018	Corresponding 3 months ended in previous period 30-Sep-2017	Year to date figures for current period ended 30-Sep-2018	Year to date figures for previous period ended 30-Sep-2017	Previous year ended 31-Mar-18
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income	-	-	8,334.00	-	16,795.60	16,795.60
Total expenses	-	-	7,453.30	-	15,088.20	15,088.20
Profit before exceptional items and tax	-	-	880.70	-	1,707.40	1,707.40
Exceptional items	-	-	-	-	-	-
Profit/(loss) before tax	-	-	880.70	-	1,707.40	1,707.40
Gain on demerger of Human API business	-	-	-	-	-	39,153.70
Tax expenses	-	-	-	-	-	-
Profit for the period	-	-	880.70	-	1,707.40	40,861.10

- 8 'Ind AS 115- Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 9 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish
Manish Gupta
Managing Director



Place : Thane

Date: 02 November 2018

SeQuent Scientific Announces 68% growth in EBITDA and 4x jump in PAT for Q2FY19

Mumbai, November 2, 2018: SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the period ended September 30, 2018

Financial Highlights

All values in ₹mn

Particulars	Q2FY19	Q2FY18	Growth (%)	H1FY19	H1FY18	Growth (%)
Revenues	2,517	1,975	27%	4,869	3,918	24.3%
EBITDA	320	190	68%	570	337	68.9%
EBITDA %	12.7%	9.6%	310 bps	11.7%	8.6%	310bps
PAT	155	42	425%	185	35	433%

Commenting on the Q2FY19 results, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: “We delivered robust 27% growth in revenue & 310 basis points margin expansion driven by improved performance across all business verticals. This has resulted in 4 fold increase in profitability for the quarter.

This is the tenth consecutive quarter of consistent growth. We believe this is result of the well defined strategy we set ourselves few years ago and our relentless focus on execution.”

Detailed presentation on the performance forms part of this press release.

Earnings Call with Investors

The Company will conduct an Earnings call at **2:30 PM IST on November 2, 2018** where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

The other numbers are listed in the conference call invite which is posted on the website of the Company.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India’s first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

sbubna@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra,
India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Abhishek Singhal

Investor Relations Consultants

abhishek.s@sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Earnings Presentation

Q2 & H1 FY19

NOVEMBER 2, 2018

More than
Pharma

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to, "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.


Q2 & H1 FY19 Performance Review

More than
Pharma

Consistent performance over quarters

“ We delivered robust 27% growth in revenue & 310 basis points margin expansion driven by improved performance across all business verticals. This has resulted in 4 fold increase in profitability for the quarter.

This is the tenth consecutive quarter of consistent growth. We believe this is the result of the well defined strategy we set ourselves few years ago and our relentless focus on execution.”



Manish Gupta
Managing Director, Sequent

Revenues										YoY	
Q2'19										2,517	27%
Q2'18										1,975	

EBITDA										YoY	
Q2'19										320	68%
Q2'18										190	

PAT										YoY	
Q2'19										152	425%
Q2'18										29	

All values in ₹ Mn

Strong performance across businesses


Revenue Distribution	Q2'19	Q2'18	YoY%	YoY% (Constant currency)
Formulations	1,777	1,449	22.7%	25.7%
<i>Europe</i>	902	720	25.3%	16.1%
<i>Turkey</i>	224	246	-8.8%	34.7%
<i>Emerging Markets</i>	402	279	44.0%	32.2%
<i>LATAM</i>	249	204	22.4%	40.2%
APIs	740	527	40.4%	28.7%
Global Sales	2,517	1,975	27.4%	26.5%

Revenue Distribution	H1'19	H1'18	YoY%	YoY% (Constant currency)
Formulations	3,527	2,870	22.9%	22.3%
<i>Europe</i>	1,829	1,440	27.0%	15.2%
<i>Turkey</i>	467	491	-4.9%	25.4%
<i>Emerging Markets</i>	776	545	42.4%	33.7%
<i>LATAM</i>	456	394	15.6%	28.9%
APIs	1,342	1,048	28.1%	18.7%
Global Sales	4,869	3,918	24.3%	21.4%

Key Highlights

Overall business delivered strong 27.4% growth YoY

- **API business** grew 40.4% - strategic focus on global top 10 animal health players bearing fruit
 - Revenue contribution from global top 10 animal health players stands at 39% vs. 28% in H1 FY16
 - Well poised to capitalise on the increasing API opportunities, given the challenges in global supply chain
- **Formulations business** grew 22.7% - significantly ahead of single digit industry growth
 - Regulated markets contribute over 50% of sales
 - Sequential improvement in Turkey post regulatory changes in Q1, on track for normalcy in H2

A large, white, stylized letter 'C' that is open on the right side, framing the central text.

Q2 & H1 FY19 Business Review

More than
Pharma

APIs

Scaling the capability curve

Revenues in ₹ Mn

H1 FY19	H1 FY 18	YoY%
1,342	1,048	28.1%

14
US Filings

10
CEP Filings

23
Other Regulated
Market Filings

14+
Pipeline

Key Highlights

- ✓ Commercial supplies commenced to US, the largest animal health market
 - ✓ Largest filings amongst generic animal health companies in US
- ✓ Margin expansion through focus on better business mix and asset utilisation
 - ✓ Deepening key customer relationships
- ✓ New product strategy around patent expiry and market scarcity

Deepening key customer relationships

API Sales



Growth Driven by Global Top 10

51%

Incremental sales between H1 FY 16 and
H1 FY 19 from Global top 10 animal health

Acquired EU-GMP API facility at Mahad

Complements our
current manufacturing
at Vizag (USFDA
approved) and Tarapur
(Intermediates)

Comprehensive manufacturing facility spread over 6 acres of land with 23 reactors having cumulative capacity of 76KL

Approved by EU-GMP & COFEPRIS Mexico, WHO-Geneva approval expected shortly

Major products: Albendazole and Ricobendazole

Consideration of ₹ 464 Mn, including working capital

Acquisition effective 1st August 2018

Formulations

Leading revenue driver

Revenues in ₹ Mn

H1 FY19	H1 FY 18	YoY%
3,527	2,870	22.9%

35+

Products Under Development

80+

Countries with marketing presence

20+


Products Launched

50%+

Sales to regulated markets

Key Highlights





- ✓ Robust growth across geographies, driven by 20+ launches and improved market share across key products
- ✓ Turkey – Sequential improvement with strong 25% growth in constant currency
- ✓ Bremer - On track for sustainable break-even by end of FY 19
- ✓ Strong R&D pipeline to maintain growth momentum – 35+ products under development

A large, white, stylized letter 'C' that is open on the right side, framing the central text.

Consistent delivery

More than
Pharma

Delivering consistent outcome over 10 quarters



Consolidated Income Statement



All values in ₹ Mn

PARTICULARS	Q2'19 Unaudited	Q1'19 Unaudited	Q2'18 Unaudited	H1'19 Unaudited	H1'18 Unaudited	FY18 Audited
Revenue from Operations	2,517	2,352	1,975	4,869	3,918	8,494
Material Consumption	(1,310)	(1,264)	(1,128)	(2,576)	(2,189)	(4,625)
Gross Margin	1,207	1,086	847	2,293	1,729	3,869
%	47.9%	46.2%	42.9%	47.1%	44.1%	45.6%
Operating Expenses	(887)	(836)	(657)	(1,723)	(1,392)	(2,998)
EBITDA	320	250	190	570	337	871
%	12.7%	10.6%	9.6%	11.7%	8.6%	10.3%
Exchange Gain / (Loss)	(42)	(25)	(1)	(67)	2	(41)
Other Income	24	18	66	43	102	166
Finance Cost	(78)	(78)	(74)	(156)	(135)	(331)
Depreciation	(102)	(96)	(101)	(198)	(201)	(413)
Exceptional Items	-	-	-	-	-	(15)
Earnings Before Tax	122	69	80	191	105	237
Taxes	33	(24)	(38)	9	(58)	(135)
Minority Interest	(3)	(12)	(13)	(15)	(13)	(93)
Earnings After Tax	152	33	29	185	35	102

Key Balance Sheet items

All values in ₹ Mn

Particulars	Mar-18	Sep-18	Comments
Shareholders' funds	6,476	6,254	Fair valuation of Strides / Solara shares
Minority Interest	370	416	
Borrowings	3,049	3,405	Mahad acquisition
Cash	598	648	
Investments	2,217	1,608	Fair valuation of Strides / Solara shares
Tangible Assets	2,269	2,514	Mahad and Bremer
Intangible Assets	2,671	2,905	Currency impact
Working Capital	2,486	2,446	



*EBITDA is H1 annualised

FY 19 Drivers

More than
Pharma

FY19 Drivers



APIs

- API business to accelerate, driven by commercialisation in US and Mahad
- Increasing penetration with 'Top 10' global animal health companies
- 4 new products to be validated, more filings in both US and EU
- 14+ API Pipeline



Formulations

- Maintain above industry growth across geographies
- Bremer to achieve breakeven by Q4'19
- 5 new product validations planned (including 2 injectables)
- 35+ FDF Pipeline



H1 Performance

- Revenue up 27% YoY
- EBITDA expansion 310 bps YoY
- Regulatory tailwinds aiding near to mid term momentum in API sales
- Regulated and key EMs driving formulation growth



FY 19

- Business on track to achieve FY19 objectives**
- 200 bps margin expansion
 - High-teen revenue growth



Thank You

SeQuent Scientific Limited

CIN: L99999MH1985PLC036685

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra
Tel No: +91 22 4111 4777 | Website: www.sequent.in | E-mail id: info@sequent.in